- Route
- LillyDirect self-pay
- Supply definition
- Four single-dose vials for 28 days
- Starting-dose offer
- $299 for 2.5 mg; not a maintenance dose
- Prescribing care
- Requires a valid prescription
One vial contains one dose
Lilly describes the single-dose vial as containing one weekly dose, with four vials in a monthly prescription. A needle and syringe are used for administration, and the manufacturer offers supplies for purchase at checkout.[source]
This is branded Zepbound in a vial, not a compounded tirzepatide preparation. The packaging format alone does not determine the medicine’s approval status.
Follow the dose-specific price table
The current self-pay schedule starts at $299 for 2.5 mg and $399 for 5 mg. Selected higher doses have a $449 offer subject to the refill conditions. The 2.5 mg presentation is a starting dose, not an approved maintenance dose.[source]
Outside the higher-dose offer, listed regular prices are $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. Program eligibility, terms and additional applicable charges need direct confirmation.
The offer includes a timing condition
Lilly’s higher-dose purchase offer requires the refill purchase within 45 days of the prior delivery or receipt. Its defined month is 28 days. These terms affect budgeting and should not be hidden behind a single from-price.[source]
A pricing condition is not medical advice about when to change or continue treatment. Clinical decisions belong with the prescriber.
Arrange the clinical relationship
LillyDirect fulfillment requires a valid prescription. Ask who provides assessment, ongoing review and side-effect support, and include any separate care charge in the budget. The pharmacy should explain the exact vial instructions.[source]
A clear branded-medication benchmark
This route is useful for readers comparing manufacturer-linked self-pay access with telehealth membership offers. Its price table is informative, provided the selected dose, supplies and prescribing cost remain visible. The ordering route itself was not a treatment arm in the head-to-head trial.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- LillyDirect: Zepbound formats and pricesManufacturer fulfillment and self-pay program terms · Checked October 8, 2026
- Lilly: Zepbound savings termsFormat-specific prices, eligibility and refill-window conditions · Checked October 8, 2026
- Zepbound prescribing informationManufacturer prescribing information, warnings and approved uses · Checked October 8, 2026